296 related articles for article (PubMed ID: 29784665)
1. SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer.
Audet-Walsh É; Vernier M; Yee T; Laflamme C; Li S; Chen Y; Giguère V
Mol Cancer Res; 2018 Sep; 16(9):1396-1405. PubMed ID: 29784665
[TBL] [Abstract][Full Text] [Related]
2. Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer.
Audet-Walsh É; Dufour CR; Yee T; Zouanat FZ; Yan M; Kalloghlian G; Vernier M; Caron M; Bourque G; Scarlata E; Hamel L; Brimo F; Aprikian AG; Lapointe J; Chevalier S; Giguère V
Genes Dev; 2017 Jun; 31(12):1228-1242. PubMed ID: 28724614
[TBL] [Abstract][Full Text] [Related]
3. Nelfinavir inhibits regulated intramembrane proteolysis of sterol regulatory element binding protein-1 and activating transcription factor 6 in castration-resistant prostate cancer.
Guan M; Fousek K; Chow WA
FEBS J; 2012 Jul; 279(13):2399-411. PubMed ID: 22540830
[TBL] [Abstract][Full Text] [Related]
4. FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth.
Du X; Wang QR; Chan E; Merchant M; Liu J; French D; Ashkenazi A; Qing J
Cancer Res; 2012 Nov; 72(22):5843-55. PubMed ID: 23019225
[TBL] [Abstract][Full Text] [Related]
5. Canonical and Nuclear mTOR Specify Distinct Transcriptional Programs in Androgen-Dependent Prostate Cancer Cells.
Chen Y; Han L; Dufour CR; Alfonso A; Giguère V
Mol Cancer Res; 2024 Feb; 22(2):113-124. PubMed ID: 37889103
[TBL] [Abstract][Full Text] [Related]
6. PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells.
Kaarbø M; Mikkelsen OL; Malerød L; Qu S; Lobert VH; Akgul G; Halvorsen T; Maelandsmo GM; Saatcioglu F
Cell Oncol; 2010; 32(1-2):11-27. PubMed ID: 20203370
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells.
Levina E; Ji H; Chen M; Baig M; Oliver D; Ohouo P; Lim CU; Schools G; Carmack S; Ding Y; Broude EV; Roninson IB; Buttyan R; Shtutman M
Oncotarget; 2015 May; 6(15):13088-104. PubMed ID: 26036626
[TBL] [Abstract][Full Text] [Related]
8. KLF5 enhances SREBP-1 action in androgen-dependent induction of fatty acid synthase in prostate cancer cells.
Lee MY; Moon JS; Park SW; Koh YK; Ahn YH; Kim KS
Biochem J; 2009 Jan; 417(1):313-22. PubMed ID: 18774944
[TBL] [Abstract][Full Text] [Related]
9. mTOR is a fine tuning molecule in CDK inhibitors-induced distinct cell death mechanisms via PI3K/AKT/mTOR signaling axis in prostate cancer cells.
Berrak O; Arisan ED; Obakan-Yerlikaya P; Coker-Gürkan A; Palavan-Unsal N
Apoptosis; 2016 Oct; 21(10):1158-78. PubMed ID: 27484210
[TBL] [Abstract][Full Text] [Related]
10. Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer.
Zhang Z; Hou X; Shao C; Li J; Cheng JX; Kuang S; Ahmad N; Ratliff T; Liu X
Cancer Res; 2014 Nov; 74(22):6635-47. PubMed ID: 25252916
[TBL] [Abstract][Full Text] [Related]
11. A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth.
Gillis JL; Hinneh JA; Ryan NK; Irani S; Moldovan M; Quek LE; Shrestha RK; Hanson AR; Xie J; Hoy AJ; Holst J; Centenera MM; Mills IG; Lynn DJ; Selth LA; Butler LM
Elife; 2021 Aug; 10():. PubMed ID: 34382934
[TBL] [Abstract][Full Text] [Related]
12. The Efflux Transporter ABCG2 Maintains Prostate Stem Cells.
Sabnis NG; Miller A; Titus MA; Huss WJ
Mol Cancer Res; 2017 Feb; 15(2):128-140. PubMed ID: 27856956
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells.
Li X; Chen YT; Josson S; Mukhopadhyay NK; Kim J; Freeman MR; Huang WC
PLoS One; 2013; 8(8):e70987. PubMed ID: 23951060
[TBL] [Abstract][Full Text] [Related]
14. Nucleoporin 62 and Ca(2+)/calmodulin dependent kinase kinase 2 regulate androgen receptor activity in castrate resistant prostate cancer cells.
Karacosta LG; Kuroski LA; Hofmann WA; Azabdaftari G; Mastri M; Gocher AM; Dai S; Hoste AJ; Edelman AM
Prostate; 2016 Feb; 76(3):294-306. PubMed ID: 26552607
[TBL] [Abstract][Full Text] [Related]
15. Interplay and cooperation between SREBF1 and master transcription factors regulate lipid metabolism and tumor-promoting pathways in squamous cancer.
Li LY; Yang Q; Jiang YY; Yang W; Jiang Y; Li X; Hazawa M; Zhou B; Huang GW; Xu XE; Gery S; Zhang Y; Ding LW; Ho AS; Zumsteg ZS; Wang MR; Fullwood MJ; Freedland SJ; Meltzer SJ; Xu LY; Li EM; Koeffler HP; Lin DC
Nat Commun; 2021 Jul; 12(1):4362. PubMed ID: 34272396
[TBL] [Abstract][Full Text] [Related]
16. Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells.
Huang WC; Li X; Liu J; Lin J; Chung LW
Mol Cancer Res; 2012 Jan; 10(1):133-42. PubMed ID: 22064655
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic activation of PI3K-AKT-mTOR signaling suppresses ferroptosis via SREBP-mediated lipogenesis.
Yi J; Zhu J; Wu J; Thompson CB; Jiang X
Proc Natl Acad Sci U S A; 2020 Dec; 117(49):31189-31197. PubMed ID: 33229547
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK/lipogenic pathway in human prostate cancer cells.
Huang WC; Zhau HE; Chung LW
J Biol Chem; 2010 Mar; 285(11):7947-56. PubMed ID: 20071336
[TBL] [Abstract][Full Text] [Related]
19. Regulation of the transcriptional coactivator FHL2 licenses activation of the androgen receptor in castrate-resistant prostate cancer.
McGrath MJ; Binge LC; Sriratana A; Wang H; Robinson PA; Pook D; Fedele CG; Brown S; Dyson JM; Cottle DL; Cowling BS; Niranjan B; Risbridger GP; Mitchell CA
Cancer Res; 2013 Aug; 73(16):5066-79. PubMed ID: 23801747
[TBL] [Abstract][Full Text] [Related]
20. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
